Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumors.
Bioinspired vesicles
Cancer treatment
Cell internalization
Cell membrane
Proteomics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 08 2024
20 08 2024
Historique:
received:
10
04
2024
accepted:
06
08
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
19
8
2024
Statut:
epublish
Résumé
Glioblastoma (GBM), one of the deadliest brain tumors, accounts for approximately 50% of all primary malignant CNS tumors, therefore novel, highly effective remedies are urgently needed. Boron neutron capture therapy, which has recently repositioned as a promising strategy to treat high-grade gliomas, requires a conspicuous accumulation of boron atoms in the cancer cells. With the aim of selectively deliver sodium borocaptate (BSH, a 12 B atoms-including molecule already employed in the clinics) to GBM cells, we developed novel cell membrane-derived vesicles (CMVs), overcoming the limits of natural extracellular vesicles as drug carriers, while maintaining their inherent homing abilities that make them preferable to fully synthetic nanocarriers. Purified cell membrane fragments, isolated from patient-derived GBM stem-like cell cultures, were used to prepare nanosized CMVs, which retained some membrane proteins specific of the GBM parent cells and were devoid of potentially detrimental genetic material. In vitro tests evidenced the targeting ability of this novel nanosystem and ruled out any cytotoxicity. The CMVs were successfully loaded with BSH, by following two different procedures, i.e. sonication and electroporation, demonstrating their potential applicability in GBM therapy.
Identifiants
pubmed: 39160236
doi: 10.1038/s41598-024-69696-7
pii: 10.1038/s41598-024-69696-7
doi:
Substances chimiques
Borohydrides
0
mercaptoundecahydrododecaborate
12294-22-3
Drug Carriers
0
Sulfhydryl Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19225Informations de copyright
© 2024. The Author(s).
Références
Maher, E. A. et al. Malignant glioma: Genetics and biology of a grave matter. Genes Dev. 15, 1311–1333 (2001).
pubmed: 11390353
doi: 10.1101/gad.891601
Florio, T. & Barbieri, F. The status of the art of human malignant glioma management: The promising role of targeting tumor-initiating cells. Drug Discov. Today 17, 1103–1110 (2012).
pubmed: 22704957
doi: 10.1016/j.drudis.2012.06.001
Ostrom, Q. T. et al. The epidemiology of glioma in adults: A ‘state of the science’ review. Neuro-Oncology 16, 896–913 (2014).
pubmed: 24842956
pmcid: 4057143
doi: 10.1093/neuonc/nou087
Grochans, S. et al. Epidemiology of glioblastoma multiforme-literature review. Cancers 14, 2412 (2022).
pubmed: 35626018
pmcid: 9139611
doi: 10.3390/cancers14102412
Furnari, F. B. et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev. 21, 2683–2710 (2007).
pubmed: 17974913
doi: 10.1101/gad.1596707
Omuro, A. & DeAngelis, L. M. Glioblastoma and other malignant gliomas: A clinical review. JAMA 310, 1842–1850 (2013).
pubmed: 24193082
doi: 10.1001/jama.2013.280319
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Gouazé-Andersson, V. & Cohen-Jonathan Moyal, E. New avenues in radiotherapy of glioblastoma: From bench to bedside. Curr. Treat. Options Neurol. 22, 45 (2020).
doi: 10.1007/s11940-020-00654-0
Ailuno, G., Baldassari, S., Lai, F., Florio, T. & Caviglioli, G. Exosomes and extracellular vesicles as emerging theranostic platforms in cancer research. Cells 9, 2569 (2020).
pubmed: 33271820
pmcid: 7761021
doi: 10.3390/cells9122569
Wu, J.-Y. et al. Exosomes and biomimetic nanovesicles-mediated anti-glioblastoma therapy: A head-to-head comparison. J. Control. Release 336, 510–521 (2021).
pubmed: 34237399
doi: 10.1016/j.jconrel.2021.07.004
Oieni, J. et al. Nano-Ghosts: Biomimetic membranal vesicles, technology and characterization. Methods Extracell. Vesicles Mimetics 177, 126–134 (2020).
Toledano Furman, N. E. et al. Reconstructed stem cell nanoghosts: A natural tumor targeting platform. Nano Lett. 13, 3248–3255 (2013).
pubmed: 23786263
doi: 10.1021/nl401376w
Liu, X., Zhong, X. & Li, C. Challenges in cell membrane-camouflaged drug delivery systems: Development strategies and future prospects. Chin. Chem. Lett. 32, 2347–2358 (2021).
doi: 10.1016/j.cclet.2021.03.015
Ren, Y. et al. Homotypic cancer cell membranes camouflaged nanoparticles for targeting drug delivery and enhanced chemo-photothermal therapy of glioma. Pharmaceuticals 15, 157 (2022).
pubmed: 35215270
pmcid: 8879672
doi: 10.3390/ph15020157
Rayamajhi, S., Nguyen, T. D. T., Marasini, R. & Aryal, S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 94, 482–494 (2019).
pubmed: 31129363
doi: 10.1016/j.actbio.2019.05.054
Hu, K. et al. Boron agents for neutron capture therapy. Coord. Chem. Rev. 405, 213139 (2020).
doi: 10.1016/j.ccr.2019.213139
Barth, R. F. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 7, 146 (2012).
pubmed: 22929110
pmcid: 3583064
doi: 10.1186/1748-717X-7-146
Miyatake, S.-I. et al. Boron neutron capture therapy of malignant gliomas. Prog. Neurol. Surg. 32, 48–56 (2018).
pubmed: 29990973
doi: 10.1159/000469679
Hiratsuka, J. et al. Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses. Cancer Commun. 38, 38 (2018).
doi: 10.1186/s40880-018-0297-9
Matsuya, Y., Fukunaga, H., Omura, M. & Date, H. A model for estimating dose-rate effects on cell-killing of human melanoma after boron neutron capture therapy. Cells 9, 1117 (2020).
pubmed: 32365916
pmcid: 7290789
doi: 10.3390/cells9051117
Barth, R. F., Mi, P. & Yang, W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun. 38, 35 (2018).
Ailuno, G. et al. Boron vehiculating nanosystems for neutron capture therapy in cancer treatment. Cells 11, 4029 (2022).
pubmed: 36552793
pmcid: 9776957
doi: 10.3390/cells11244029
Wu, J.-Y. et al. Multifunctional exosome-mimetics for targeted anti-glioblastoma therapy by manipulating protein corona. J. Nanobiotechnol. 19, 405 (2021).
doi: 10.1186/s12951-021-01153-3
Jia, Y. et al. Phototheranostics: Active targeting of orthotopic glioma using biomimetic proteolipid nanoparticles. ACS Nano 13, 386–398 (2019).
pubmed: 30576599
doi: 10.1021/acsnano.8b06556
Guo, Y. et al. Eliminating the original cargos of glioblastoma cell-derived small extracellular vesicles for efficient drug delivery to glioblastoma with improved biosafety. Bioact. Mater. 16, 204–217 (2022).
pubmed: 35386327
pmcid: 8965721
Lu, G. et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat. Commun. 13, 4214 (2022).
pubmed: 35864093
pmcid: 9304377
doi: 10.1038/s41467-022-31799-y
Chen, H. et al. Biomimetic nanosonosensitizers combined with noninvasive ultrasound actuation to reverse drug resistance and sonodynamic-enhanced chemotherapy against orthotopic glioblastoma. ACS Nano 17, 421–436 (2023).
pubmed: 36573683
doi: 10.1021/acsnano.2c08861
Barbieri, F. et al. Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives. J. Exp. Clin. Cancer Res. CR 41, 53 (2022).
pubmed: 35135603
doi: 10.1186/s13046-021-02213-0
Barbieri, F. et al. Inhibition of chloride intracellular channel 1 (CLIC1) as biguanide class-effect to impair human glioblastoma stem cell viability. Front. Pharmacol. 9, 899 (2018).
pubmed: 30186163
pmcid: 6110922
doi: 10.3389/fphar.2018.00899
Griffero, F. et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors*. J. Biol. Chem. 284, 7138–7148 (2009).
pubmed: 19147502
pmcid: 2652334
doi: 10.1074/jbc.M807111200
Yerneni, S. S. et al. Skin-targeted delivery of extracellular vesicle-encapsulated curcumin using dissolvable microneedle arrays. Acta Biomater. 149, 198–212 (2022).
pubmed: 35809788
doi: 10.1016/j.actbio.2022.06.046
Bajetto, A. et al. different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front. Cell. Neurosci. 11, 312 (2017).
pubmed: 29081734
pmcid: 5645520
doi: 10.3389/fncel.2017.00312
Barbieri, F. et al. Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity. Neuro-Oncology 25, 1775–1787 (2023).
pubmed: 37074930
pmcid: 10547527
doi: 10.1093/neuonc/noad076
Richter, M. et al. From donor to the lab: A fascinating journey of primary cell lines. Front. Cell Dev. Biol. 9, 711381 (2021).
pubmed: 34395440
pmcid: 8356673
doi: 10.3389/fcell.2021.711381
Würth, R. et al. Phenotypical and pharmacological characterization of stem-like cells in human pituitary adenomas. Mol. Neurobiol. 54, 4879–4895 (2017).
pubmed: 27514754
doi: 10.1007/s12035-016-0025-x
Suski, J. M. et al. Isolation of plasma membrane–associated membranes from rat liver. Nat. Protoc. 9, 312–322 (2014).
pubmed: 24434800
doi: 10.1038/nprot.2014.016
Austin, J., Minelli, C., Hamilton, D., Wywijas, M. & Jones, H. J. Nanoparticle number concentration measurements by multi-angle dynamic light scattering. J. Nanoparticle Res. 22, 108 (2020).
doi: 10.1007/s11051-020-04840-8
Ailuno, G. et al. Development of biotinylated liposomes encapsulating metformin for therapeutic targeting of inflammation-based diseases. Pharmaceutics 16, 235 (2024).
pubmed: 38399288
pmcid: 10893420
doi: 10.3390/pharmaceutics16020235
Sharma, M. C. Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers. Int. J. Cancer 144, 2074–2081 (2019).
pubmed: 30125343
doi: 10.1002/ijc.31817
Lubanska, D. et al. Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles. Sci. Rep. 12, 12078 (2022).
pubmed: 35840697
pmcid: 9287456
doi: 10.1038/s41598-022-15244-0
Rose, M. et al. Surfaceome proteomic of glioblastoma revealed potential targets for immunotherapy. Front. Immunol. 12, 746168 (2021).
pubmed: 34646273
pmcid: 8503648
doi: 10.3389/fimmu.2021.746168
Mallawaaratchy, D. M. et al. Membrane proteome analysis of glioblastoma cell invasion. J. Neuropathol. Exp. Neurol. 74, 425–441 (2015).
pubmed: 25853691
doi: 10.1097/NEN.0000000000000187
Hedhli, N. et al. The annexin A2/S100A10 system in health and disease: Emerging paradigms. J. Biomed. Biotechnol. 2012, 406273 (2012).
pubmed: 23193360
pmcid: 3496855
doi: 10.1155/2012/406273
Matsumoto, Y. et al. Annexin A2-STAT3-oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma. Acta Neuropathol. Commun. 8, 42 (2020).
pubmed: 32248843
pmcid: 7132881
doi: 10.1186/s40478-020-00916-7
Maule, F. et al. Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget 7, 54632–54649 (2016).
pubmed: 27429043
pmcid: 5342369
doi: 10.18632/oncotarget.10565
Zhai, H. et al. Annexin A2 promotes glioma cell invasion and tumor progression. J. Neurosci. Off. J. Soc. Neurosci. 31, 14346–14360 (2011).
doi: 10.1523/JNEUROSCI.3299-11.2011
Zeng, H. et al. Current strategies for exosome cargo loading and targeting delivery. Cells 12, 1416 (2023).
pubmed: 37408250
pmcid: 10216928
doi: 10.3390/cells12101416
Hirase, S. et al. Dodecaborate-encapsulated extracellular vesicles with modification of cell-penetrating peptides for enhancing macropinocytotic cellular uptake and biological activity in boron neutron capture therapy. Mol. Pharm. 19, 1135–1145 (2022).
pubmed: 35298163
doi: 10.1021/acs.molpharmaceut.1c00882
Pomatto, M. A. C. et al. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol. Ther. Methods Clin. Dev. 13, 133–144 (2019).
pubmed: 30788382
pmcid: 6370572
doi: 10.1016/j.omtm.2019.01.001